The investment firm noted that recently released results from the Phase 1 Helios study of Axpaxli in non-proliferative diabetic retinopathy, or NPDR, showed no notable safety issues. It added that ...

SOL-R, Ocular’s second registrational trial of AXPAXLI™ in wet AMD, as of January 10, 2024 First wet AMD registrational trial ...

DR was graded according to early Treatment Diabetic Retinopathy (ETDRS ... (70.35%), which included 34 patients (17.1%) with mild non proliferative DR (NPDR), 34 patients (17.1%) with moderate ...

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients ...

This stage of diabetic retinopathy always requires urgent treatment. The condition has two stages – non-proliferative retinopathy is the early stage of the disease in which blood vessels swell ...

Ocular Therapeutix (OCUL) plans to advance AXPAXLI in non-proliferative diabetic retinopathy, NPDR, and the Company’s strategic outlook for 2025 in its presentation at the 43rd Annual J.P ...

9 The spectrum of DR severity ranges from non-proliferative diabetic retinopathy (NPDR) to proliferative diabetic retinopathy (PDR).4 As DR progresses, a large proportion of patients develop ...

Although laser photocoagulation is an effective treatment for proliferative diabetic retinopathy, few options were available at that time for wet AMD (Box 1). Visual acuity tests are the most ...

He added that the totality of the data in non-proliferative diabetic retinopathy suggests clinical activity at "certain doses" and supports further clinical evaluation of the drug in this indication.

Topline data from SOL-1 is expected in the fourth quarter of 2025, and the company intends to consult with the FDA on trial designs for AXPAXLI in non-proliferative diabetic retinopathy (NPDR ...